Updated POLLUX results for early relapsed myeloma patients

Updated POLLUX results for early relapsed myeloma patients

VJHemOnc

1 year
939 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Saad Usmani, MD, of the University of North Carolina School of Medicine, Chapel Hill, NC, updates us at the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France, on the results from the POLLUX trial (NCT02076009). Dr Usmani describes the overall median survival, median progression-free survival, and measurable residual disease data in early relapsed myeloma patients receiving daratumumab, lenalidomide and dexamethasone treatment.
Up Next Autoplay